Aralıklı Açlık (IF) ve Kanser: Literatürün Gözden Geçirilmesi DOI Open Access
Büşra Yurt Türer, Pınar Göbel

Journal of Nutrition and Dietetics, Journal Year: 2023, Volume and Issue: 51(3), P. 79 - 90

Published: Dec. 30, 2023

Günümüzde tüm dünyada yaşanan ölümlerde payı yüksek olan kanser, bulaşıcı olmayan kronik hastalıklardan biridir. Bunun yanında kanser insidansı ve buna bağlı ölüm oranı her geçen gün artmaktadır. Kanser hastalığından ölen insan sayısı 2018 yılında 9.6 milyon iken tahminler 2030 bu sayının 13.2 milyona ulaşacağını göstermektedir. Kanser, genetik yatkınlık, ırk, cinsiyet gibi değiştirilemeyen faktörlerin yanı sıra sedanter yaşam, obezite, sağlıksız beslenme değiştirilebilen faktörlerden kaynaklı ortaya çıkabilen çok faktörlü bir hastalıktır. kansere karşı henüz kesin tedavi bulunamaması yönelik uygulanan yöntemlerinin yan etkilere yol açması farklı stratejilere ihtiyacı arttırmıştır. Bu derlemede potansiyel strateji olarak açlık (F) aralıklı (IF) incelenmiştir. Yapılan çalışmalarda; açlığın, sağlıklı hücreleri yavaş büyümeye sevk ettiği, antikanser ilaçların toksik etkisine koruduğu hücrelerini terapötiklere daha duyarlı hale getirdiğinden bahsedilmektedir. çalışmalar açlığın terapötik etkileri konusunda umut vericidir. Fakat çalışmalardan elde edilen sonuçlar oldukça riskli hassas grup hastalarında klinik uygulama için yeterli olmadığını

Nanoparticle innovations in targeted cancer therapy: advancements in antibody–drug conjugates DOI Creative Commons
Magdi T. Abdelhamid, Al-Hassan Soliman Wadan,

Hosam A. Saad

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 18, 2025

Language: Английский

Citations

4
Overview of the epigenetic/cytotoxic dual-target inhibitors for cancer therapy DOI

Hailiu Liang,

Shuqing Li, Xiaopeng Peng

et al.

European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: 285, P. 117235 - 117235

Published: Jan. 5, 2025

Language: Английский

Citations

1
Applications of self-assembled peptide hydrogels in anti-tumor therapy DOI Creative Commons

Yue Hua,

Yang Shen

Nanoscale Advances, Journal Year: 2024, Volume and Issue: 6(12), P. 2993 - 3008

Published: Jan. 1, 2024

Peptides are a class of active substances composed variety amino acids with special physiological functions.

Language: Английский

Citations

5
Co-Delivery of Docetaxel and Curcumin Functionalized Mixed Micelles for the Treatment of Drug-Resistant Breast Cancer by Oral Administration DOI Creative Commons

Chengyang Dian,

Z Qian,

Mengnan Ran

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 8603 - 8620

Published: Aug. 1, 2024

Chemotherapeutic drugs have some drawbacks in antineoplastic therapy, mainly containing seriously toxic side effects caused by injection and multi-drug resistance (MDR). Co-delivery with two or more via nanomicelles is a promising strategy to solve these problems. Oral chemotherapy increasingly preferred owing its potential enhance the life quality of patients.

Language: Английский

Citations

5
The cytotoxic and antiproliferative effect of Polygala saponin XLIV on the human colorectal carcinoma cell line DOI Creative Commons
Eda Becer, Azmi Hanoğlu, Ayşe Ünlü

et al.

Turkish Journal of Biochemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 6, 2025

Abstract Objectives Saponins are secondary metabolites naturally found in plants with diverse pharmacological properties such as anticancer. This research aimed to explore the anti-cancer of Polygalasaponin XLIV (PS-XLIV) a human colorectal carcinoma cell line derived from Polygala vulgaris roots. Methods HCT166 cells were treated different PS-XLIV concentrations and incubated for 24 48 h. We used immunocytochemistry investigate PS-XLIV’s properties, employing antibodies targeting WNT3A, WNT11, STAT3, β-catenin, Ki-67. The IC50 value was 80 μg/mL HCT116 cells. Immunoreactivities significantly decreased PS-XLIV-treated than control group Results After treatment, epithelial morphology protected; however, number less that While WNT3A immunoreactivity similar both groups, WNT11 β-catenin immunoreactivities after application. In addition, exhibited weaker Ki-67 immunoreactivity, STAT3 immunoreactivty moderated Conclusions For first time, anticancer effects isolated P. on shown. effect may involve reducing activation pathways

Language: Английский

Citations

0
The effects of intermittent fasting on anthropometric indices, glycemic profile, chemotherapy-related toxicity, and subjective perception in gynecological and breast cancer patients: a systematic review and meta-analysis DOI Creative Commons
Xiaoxia Liu, Qing H. Meng,

Wenqi Fan

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 7, 2025

Mounting evidence supports the health benefits of intermittent fasting (IF) in general. This study evaluates its impact on patients with gynecological or breast cancer specifically. A thorough search for studies comparing IF either nonintervention diets calorie restriction (CR) and published prior to October 5, 2024 was carried out PubMed, Web Science, Cochrane Library, Scopus, Embase, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature databases (CBM). Extracted data included but not limited body mass index (BMI), weight, waist circumference (WC), glucose, insulin levels, chemotherapy-related toxicity, subjective perceptions. total 625 subjects were across 7 randomized controlled trials, 2 nonrandomized trials. Meta-analysis revealed that significantly reduced weight (Effect Size [ES]: -0.611; 95% Confidence Interval [CI]: -0.886 -0.356; p < 0.001; I² = 0%), blood glucose levels (standardized mean difference [SMD]: -0.347 mmol/L; CI: -0.533 -0.140; 0.001), concentrations (SMD: -0.395 mU/L; -0.674 -0.116; 0.005). Sensitivity analysis indicated overall effect sizes stable. However, it remains uncertain whether increases adverse effects (relative risk [RR]: 1.038; 0.844 1.278; 0.723). Furthermore, three fatigue two improved quality life. systematic review meta-analysis suggests has a beneficial reducing patients. may also reduce improve is uncertain. Further high-quality long-term follow-ups are needed confirm these findings.

Language: Английский

Citations

0
Fasting as Cancer Treatment: Myth or Breakthrough in Oncology DOI Open Access

Ghizal Fatima,

Abbas A Mehdi,

Ján Fedačko

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: March 29, 2025

The concept of fasting as a potential cancer treatment has garnered increasing interest, particularly in light emerging evidence linking dietary interventions to progression and therapy outcomes. This article explores whether fasting, either intermittent or prolonged, can be viable standalone for if its therapeutic lies adjunctive role. Current research suggests that induces metabolic shift, which may inhibit cell proliferation by depriving them essential nutrients. Additionally, been shown enhance the body's stress resistance, promote autophagy, possibly make cells more vulnerable standard treatments such chemotherapy radiotherapy. However, application sole remains controversial lacks substantial clinical validation. While animal models vitro studies indicate promising results, translation human trials is complex, with various types responding differently interventions. Moreover, concerns about malnutrition, loss muscle mass, overall health patients undergoing without supervision must addressed. paper critically examines myth reality surrounding treatment, reviewing key provide comprehensive understanding efficacy safety. hold promise supportive therapy, combination traditional treatments, there currently insufficient support use primary modality. Further needed establish parameters might beneficial, specific types, patient populations, optimal regimens. Thus, while idea breakthrough compelling, it complementary approach rather than solution oncology.

Language: Английский

Citations

0
Multifunctional DNA nano-sponge system for targeted sensitization of ovarian cancer chemotherapy via metabolic reprogramming and ferroptosis induction DOI
Kejun Dong, Hao Hu,

Cheng Jun.SHI Shuang-shuang

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113663 - 113663

Published: March 1, 2025

Language: Английский

Citations

0
Unraveling the impact of intermittent fasting in cancer prevention, mitigation, and treatment: A narrative review DOI
MoezAlIslam E. Faris,

Dania Husam Alkawamleh,

Mohamed Madkour

et al.

journal of nutritional oncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Intermittent fasting (IF) has emerged as a potential adjunctive strategy in cancer prevention, mitigation, and treatment. This narrative review synthesizes existing literature to explore the relationship between IF across 3 dimensions: We examine underlying mechanisms by which may reduce risk, including its effects on insulin-like growth factor 1 suppression, autophagy induction, chronic inflammation reduction. Furthermore, we discuss IF’s enhance efficacy of conventional therapies sensitizing cells, promoting apoptosis, reducing treatment-related side effects. While promising, evidence is still limited, further research required elucidate long-term impact optimal implementation care. aims provide health care professionals patients with comprehensive understanding benefits risks associated complementary approach oncology setting.

Language: Английский

Citations

0
ShenJiaoLingCao Decoction ameliorates cyclophosphamide-induced splenic injury and immunosuppression via the inhibition of MEK/ERK signaling pathway activity and modulation of amino acid metabolism DOI Creative Commons
Yuzhen Liu, Zhe Wu, Chen Gu

et al.

Journal of Ethnopharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 119830 - 119830

Published: April 1, 2025

Language: Английский

Citations

0